187 related articles for article (PubMed ID: 25885571)
1. The changing patterns of dispensing branded and generic drugs for the treatment of gastroesophageal reflux disease between 2006 and 2011 in Japan: a retrospective cohort study.
Murata K; Hinotsu S; Hamada S; Ezoe Y; Muto M; Kawakami K
BMC Health Serv Res; 2015 Feb; 15():76. PubMed ID: 25885571
[TBL] [Abstract][Full Text] [Related]
2. Analyzing generic and branded substitution patterns in the Netherlands using prescription data.
Pechlivanoglou P; van der Veen WJ; Bos JH; Postma MJ
BMC Health Serv Res; 2011 Apr; 11():89. PubMed ID: 21524312
[TBL] [Abstract][Full Text] [Related]
3. Medical cost, incidence rate, and treatment status of gastroesophageal reflux disease in Japan: analysis of claims data.
Miwa H; Takeshima T; Iwasaki K; Hiroi S
J Med Econ; 2016 Nov; 19(11):1049-1055. PubMed ID: 27207316
[TBL] [Abstract][Full Text] [Related]
4. Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.
Kothari S; Nelson SP; Wu EQ; Beaulieu N; McHale JM; Dabbous OH
Curr Med Res Opin; 2009 Nov; 25(11):2703-9. PubMed ID: 19775195
[TBL] [Abstract][Full Text] [Related]
5. Prescribing trends of proton pump inhibitors and histamine blockers among children in the United Kingdom (1998-2019): A population-based assessment.
Masarwa R; Reynier P; Lefebvre C; Platt RW; Delaney JAC; Filion KB
Pharmacoepidemiol Drug Saf; 2024 Feb; 33(2):e5752. PubMed ID: 38362652
[TBL] [Abstract][Full Text] [Related]
6. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study.
El-Serag HB; Fitzgerald S; Richardson P
Am J Gastroenterol; 2009 Sep; 104(9):2161-7. PubMed ID: 19568229
[TBL] [Abstract][Full Text] [Related]
7. How Do US Gastroenterologists Use Over-the-Counter and Prescription Medications in Patients With Gastroesophageal Reflux and Chronic Constipation?
Menees SB; Guentner A; Chey SW; Saad R; Chey WD
Am J Gastroenterol; 2015 Nov; 110(11):1516-25. PubMed ID: 26054623
[TBL] [Abstract][Full Text] [Related]
8. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists.
Andrade SE; Gurwitz JH; Fish LS
Med Care; 1999 Apr; 37(4):424-30. PubMed ID: 10213023
[TBL] [Abstract][Full Text] [Related]
9. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
Carroll NV
J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
[TBL] [Abstract][Full Text] [Related]
10. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
11. Short-term treatment of gastroesophageal reflux disease.
van Pinxteren B; Numans ME; Lau J; de Wit NJ; Hungin AP; Bonis PA
J Gen Intern Med; 2003 Sep; 18(9):755-63. PubMed ID: 12950485
[TBL] [Abstract][Full Text] [Related]
12. Age, specialty, and practice setting predict gastroesophageal reflux disease prescribing behavior.
Lacy BE; Crowell MD; Riesett RP; Mitchell A
J Clin Gastroenterol; 2005 Jul; 39(6):489-94. PubMed ID: 15942434
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of treatment pattern and symptom control in patients with gastroesophageal reflux disease: multihospital questionnaire survey on the current situation in Korea.
Seo SI; Bang CS; Kang HS; Choi MH; Shin WG; Jang HJ; Kim JB; Baik KH; Kae SH; Kim HY
Dis Esophagus; 2017 Oct; 30(10):1-8. PubMed ID: 28859382
[TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitor prescribing and costs in a large outpatient clinic.
Hood W; McJunkin B; Warnock A; Girme A; Smith N; Robinson B
W V Med J; 2014; 110(1):16-21. PubMed ID: 24640269
[TBL] [Abstract][Full Text] [Related]
15. Treatment of gastroesophageal reflux disease.
Pettit M
Pharm World Sci; 2005 Dec; 27(6):432-5. PubMed ID: 16341949
[TBL] [Abstract][Full Text] [Related]
16. Prospective Study of Gastroesophageal Reflux, Use of Proton Pump Inhibitors and H2-Receptor Antagonists, and Risk of Hearing Loss.
Lin BM; Curhan SG; Wang M; Jacobson BC; Eavey R; Stankovic KM; Curhan GC
Ear Hear; 2017; 38(1):21-27. PubMed ID: 27556519
[TBL] [Abstract][Full Text] [Related]
17. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
[TBL] [Abstract][Full Text] [Related]
18. Practice patterns of reflux medication prescriptions in otolaryngology compared to other specialties.
Luetzenberg FS; Jiang N
Laryngoscope; 2020 Feb; 130(2):321-327. PubMed ID: 30861137
[TBL] [Abstract][Full Text] [Related]
19. Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
Jonasson C; Tvete IF; Hatlebakk JG
Scand J Gastroenterol; 2013 Sep; 48(9):1010-7. PubMed ID: 23859491
[TBL] [Abstract][Full Text] [Related]
20. Analysis of costs to dispense prescriptions in independently owned, closed-door long-term care pharmacies.
Carroll NV; Rupp MT; Holdford DA
J Manag Care Spec Pharm; 2014 Mar; 20(3):291-300. PubMed ID: 24564809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
